Page 62 - 8_04
P. 62
Solid lipid nanoparticles for gene therapy 22. Bose RJ, Arai Y, Ahn JC, Park H, Lee SH. Influence of
cationic lipid concentration on properties of lipid-
5. Phua KK, Nair SK, Leong KW. Messenger RNA polymer hybrid nanospheres for gene delivery. Int J
(mRNA) nanoparticle tumour vaccination. Nanoscale Nanomedicine 2015; 10: 5367-82.
2014; 6: 7715-29.
23. Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid
6. Rodríguez-Gascón A, del Pozo-Rodríguez A, Solinís lipid nanoparticles (SLN) for controlled drug delivery.
MA. Development of nucleic acid vaccines: use of I. Production, characterization and sterilization. J
self-amplifying RNA in lipid nanoparticles. Int J Control Rel 1994; 30: 83-96.
Nanomedicine 2014; 9: 1833-43.
24. del Pozo-Rodríguez A, Solinís MA, Gascón AR,
7. Lares MR, Rossi JJ, Ouellet DL. RNAi and small Pedraz JL. Short- and long-term stability study of
interfering RNAs in human disease therapeutic lyophilized solid lipid nanoparticles for gene therapy.
applications. Trends Biotechnol 2010; 28: 570-9. Eur J Pharm Biopharm 2009; 71: 181-9.
8. Moore CB, Guthrie EH, Huang MT, Taxman DJ. Short 25. Swathi G, Prasanthi NL, Manikiran SS, Ramarao N.
hairpin RNA (shRNA): design, delivery, and Solid Lipid Nanoparticles: Colloidal Carrier Systems
assessment of gene knockdown. Methods Mol Biol for Drug Delivery. IJPSR 2010; 1:1-16.
2010; 629: 141-58.
26. Müller RH, Radtke M, Wissing SA. Solid lipid
9. Zhang Y, Wang Z, Gemeinhart RA. Progress in nanoparticles (SLN) and nanostructured lipid carriers
microRNA delivery. J Control Release 2013; 172: (NLC) in cosmetic and dermatological preparations.
962–974. Adv Drug Deliv Rev 2002; 54 (Suppl): S131-S55.
10. Liu F, Shollenberger LM, Conwell CC, Yuan X, 27. Olbrich C, Bakowsky U, Lehr C-M, Müller RH,
Huang L. Mechanism of naked DNA clearance after Kneuer C. Cationic solid-lipid nanoparticles can
intravenous injection. J Gene Med 2007; 9: 613-619. efficiently bind and transfect plasmid DNA. J Control
Release 2001; 77: 345-55.
11. Rodríguez-Gascón A, del Pozo-Rodríguez A, Isla A,
Solinís MA. Vaginal gene therapy. Adv Drug Deliv 28. Rodríguez-Gascón A, Solinís MA, del Pozo-Rodríguez
Rev 2015; 92: 71-83. A, Delgado D, Pedraz JL, inventors; University of the
Basque Country UPV/EHU, assignee. Lipid
12. Del Pozo-Rodríguez A, Solinís MA, Gascón AR, Nanoparticles For Gene Therapy, P200901664,
Pedraz JL. Terapia génica. Concepto, sistemas de PCT/ES/2010/070519, WO 2011/015701 A3,
administración y aplicaciones. Industria Farmacéutica US2012/0183589 A1, 2011.
2006; 128: 86-99.
29. Rodríguez-Gascón A, Solinís MA, del Pozo-Rodríguez
13. The Journal of Gene Medicine Clinial Trial Site. 2016. A, Delgado D, Fernández E, inventors; University of
Jon Wiley and Sons Ltd. Disponible en the Basque Country UPV/EHU, Universidad Miguel
http://www.wiley.com/legacy/wileychi/genmed/clinic Hernández de Elche, assignees Lipid Nanoparticles
al/. for Treating Ocular Diseases. P201031897,
PCT/ES2011/070883, US2013/0234592 A1,
14. Sheridan C. Gene therapy finds its niche. Nat WO2011015701 (A3), 2012.
Biotechnol 2011; 29: 121-8.
30. Ruiz de Garibay AP, Solinís MA, del Pozo-Rodríguez
15. Molla MR, Levkin PA. Combinatorial Approach to A, Apaolaza PS, Shen JS, Rodríguez-Gascón A. Solid
Nanoarchitectonics for Nonviral Delivery of Nucleic lipid nanoparticles as non-viral vectors for gene
Acids. Adv Mater 2016; 28: 1159-1175. transfection in a cell model of Fabry disease. J
Biomed Nanotechnol 2015; 11: 500-11.
16. Ramamoorth M, Narvekar A. Non viral vectors in gene
therapy-an overview. J Clin Diagn Res 2015; 9: 31. Torrecilla J, del Pozo-Rodríguez A, Apaolaza PS,
GE01-6. Solinís MA, Rodríguez-Gascón A. Solid lipid
nanoparticles as non-viral vector for the treatment of
17. Rodríguez-Gascón A, del Pozo-Rodríguez A, Solinís chronic hepatitis C by RNA interference. Int J Pharm
MA. Non-viral delivery systems in gene therapy. In 2015; 479: 181-8.
Martín-Molina F, Ed. Gene Therapy. Tools and
potential applications. Croatia: Intech 2013 pp: 3-33. 32. Torrecilla J, del Pozo-Rodríguez A, Solinís MA, et al.
Silencing of hepatitis C virus replication by a non-
18. Young JL, Dean DA. Electroporation-mediated gene viral vector based on solid lipid nanoparticles
delivery. Adv Genet 2015; 89: 49-88. containing a shRNA targeted to the internal ribosome
entry site (IRES). Colloids Surf B Biointerfaces 2016;
19. Stoller F, Schlegel A, Viecelli HM, et al. Hepatocyte 146: 808-17.
Transfection in small pigs after weaning by
hydrodynamic intraportal injection of naked 33. Apaolaza PS, Del Pozo-Rodríguez A, Torrecilla J, et
DNA/minicircle vectors. Hum Gene Ther Methods al. Solid lipid nanoparticle-based vectors intended for
2015; 26: 181-92. the treatment of X-linked juvenile retinoschisis by
gene therapy: In vivo approaches in Rs1h-deficient
20. Pan R, Xu W, Ding Y, Lu S, Chen P. Uptake mouse model. J Control Release 2015; 217: 273-83.
mechanism and direct translocation of a new CPP for
siRNA delivery. Mol Pharm 2016; 13: 1366-74. 421
21. Wang M, Wu B, Tucker JD, Lu P, Lu Q. Poly(ester
amine) Constructed from Polyethylenimine and
Pluronic for Gene Delivery in vitro and in vivo. Drug
Deliv 2016; 10: 1-23.
@Real Academia Nacional de Farmacia. Spain
